The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2017Farnesoid X Receptor to Reduce Neuroinflammation
Study Rationale:
Although the precise mechanism(s) for neurodegeneration in Parkinson's disease (PD) is unknown, evidence suggests that neuroinflammation is an important contributor. In this study, we... -
Therapeutic Pipeline Program, 2017Small-Molecule Inhibitor of Alpha-Synuclein Propagation in the Treatment of Parkinson's Disease
Study Rationale:
The notion of misfolded alpha-synuclein (alpha-syn) aggregates moving from neuron-to-neuron is a mechanism that is gaining widespread acceptance as a central mechanism in the... -
Therapeutic Pipeline Program, 2017Pre-clinical Development of LBT-3627, a Potential Neuroprotective and Anti-inflammatory Therapy for Parkinson's Disease
Study Rationale:
Adaptive and innate immune responses play important roles in neuroinflammation and can be harnessed to improve outcomes in Parkinson's disease (PD). Daily administration of LBT-3627... -
Research Grant, 2017Microbiome Biomarkers for Early-stage Detection and Stratification of Parkinson's Disease
Study Rationale:
Parkinson's disease (PD) research benefits from knowledge of disease-specific risk and resilience factors and elucidation of pathophysiological concepts on the emergence of... -
Research Grant, 2017Study of a Molecule to Prevent Alpha-Synuclein Clumping and Treat Parkinson's Disease
Promising Outcomes of Original Grant:
Alpha-synuclein is a sticky protein that clumps in the brains of people with Parkinson's disease (PD). In our first project funded by The Michael J. Fox Foundation... -
LRRK2 Therapeutic and Safety Initiative, 2017Efficacy and Safety of Chronic Treatment with LRRK2 Inhibitors
Study Rationale:
LRRK2 inhibitors are among the most promising in the current generation of potential novel treatments for Parkinson's disease (PD). In pre-clinical models, long-term treatment with...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.